Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Durvalumab companion diagnostic - AstraZeneca/Roche Tissue Diagnostics

Next Previous
Search
Drug Profile

Durvalumab companion diagnostic - AstraZeneca/Roche Tissue Diagnostics

Alternative Names: MEDI-4736 companion diagnostic - AstraZeneca/Roche Tissue Diagnostics; VENTANA PD-L1 (SP 263) Assay

Latest Information Update: 29 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune; Ventana Medical Systems
  • Developer MedImmune; Roche Tissue Diagnostics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Urogenital cancer
  • No development reported Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 23 Aug 2022 VENTANA PD-L1 (SP 263) assay gains CE label expansion in non-small cell lung cancer (NSCLC) as a companion diagnostic for Tecentriq® (atezolizumab).
  • 13 Jul 2021 Ventana Medical Systems is now called Roche Tissue Diagnostics
  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Head-and-neck-cancer(Diagnosis) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top